nodes	percent_of_prediction	percent_of_DWPC	metapath
Tranylcypromine—CYP2E1—Fingolimod—multiple sclerosis	0.161	0.198	CbGbCtD
Tranylcypromine—CYP2A6—Prednisolone—multiple sclerosis	0.101	0.124	CbGbCtD
Tranylcypromine—CYP2D6—Fingolimod—multiple sclerosis	0.0765	0.0942	CbGbCtD
Tranylcypromine—CYP2E1—Mitoxantrone—multiple sclerosis	0.0755	0.0929	CbGbCtD
Tranylcypromine—CYP2A6—Dexamethasone—multiple sclerosis	0.0593	0.073	CbGbCtD
Tranylcypromine—CYP3A4—Fingolimod—multiple sclerosis	0.0486	0.0599	CbGbCtD
Tranylcypromine—CYP2C19—Prednisone—multiple sclerosis	0.0393	0.0484	CbGbCtD
Tranylcypromine—CYP2E1—Dexamethasone—multiple sclerosis	0.0391	0.0482	CbGbCtD
Tranylcypromine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0313	0.0386	CbGbCtD
Tranylcypromine—CYP2C19—Dexamethasone—multiple sclerosis	0.0245	0.0302	CbGbCtD
Tranylcypromine—CYP3A4—Triamcinolone—multiple sclerosis	0.0238	0.0292	CbGbCtD
Tranylcypromine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0229	0.0282	CbGbCtD
Tranylcypromine—CYP2C9—Dexamethasone—multiple sclerosis	0.0204	0.0251	CbGbCtD
Tranylcypromine—CYP3A4—Betamethasone—multiple sclerosis	0.0204	0.0251	CbGbCtD
Tranylcypromine—CYP3A4—Prednisolone—multiple sclerosis	0.0201	0.0248	CbGbCtD
Tranylcypromine—CYP3A4—Prednisone—multiple sclerosis	0.019	0.0234	CbGbCtD
Tranylcypromine—CYP2D6—Dexamethasone—multiple sclerosis	0.0186	0.023	CbGbCtD
Tranylcypromine—CYP3A4—Dexamethasone—multiple sclerosis	0.0119	0.0146	CbGbCtD
Tranylcypromine—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.00175	0.0417	CbGpPWpGaD
Tranylcypromine—MAOB—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00104	0.0247	CbGpPWpGaD
Tranylcypromine—MAOB—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00104	0.0247	CbGpPWpGaD
Tranylcypromine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000776	0.0185	CbGpPWpGaD
Tranylcypromine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000776	0.0185	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—PLP1—multiple sclerosis	0.000766	0.0182	CbGpPWpGaD
Tranylcypromine—CYP2A6—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000762	0.0181	CbGpPWpGaD
Tranylcypromine—MAOA—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000651	0.0155	CbGpPWpGaD
Tranylcypromine—MAOA—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000651	0.0155	CbGpPWpGaD
Tranylcypromine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000623	0.0148	CbGpPWpGaD
Tranylcypromine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000623	0.0148	CbGpPWpGaD
Tranylcypromine—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000615	0.0146	CbGpPWpGaD
Tranylcypromine—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000615	0.0146	CbGpPWpGaD
Tranylcypromine—MAOB—Biological oxidations—CYP27B1—multiple sclerosis	0.000551	0.0131	CbGpPWpGaD
Tranylcypromine—MAOB—Biological oxidations—CYP24A1—multiple sclerosis	0.000551	0.0131	CbGpPWpGaD
Tranylcypromine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000546	0.013	CbGpPWpGaD
Tranylcypromine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000546	0.013	CbGpPWpGaD
Tranylcypromine—MAOA—Serotonin Transporter Activity—IL1B—multiple sclerosis	0.000521	0.0124	CbGpPWpGaD
Tranylcypromine—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000505	0.012	CbGpPWpGaD
Tranylcypromine—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000505	0.012	CbGpPWpGaD
Tranylcypromine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000493	0.0117	CbGpPWpGaD
Tranylcypromine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000493	0.0117	CbGpPWpGaD
Tranylcypromine—Asthenia—Cladribine—multiple sclerosis	0.000492	0.00344	CcSEcCtD
Tranylcypromine—Bradycardia—Triamcinolone—multiple sclerosis	0.000488	0.00341	CcSEcCtD
Tranylcypromine—Bradycardia—Methylprednisolone—multiple sclerosis	0.000487	0.0034	CcSEcCtD
Tranylcypromine—CYP2E1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000486	0.0116	CbGpPWpGaD
Tranylcypromine—CYP2E1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000486	0.0116	CbGpPWpGaD
Tranylcypromine—Haemoglobin—Triamcinolone—multiple sclerosis	0.000482	0.00337	CcSEcCtD
Tranylcypromine—Haemoglobin—Methylprednisolone—multiple sclerosis	0.00048	0.00336	CcSEcCtD
Tranylcypromine—Haemorrhage—Triamcinolone—multiple sclerosis	0.000479	0.00335	CcSEcCtD
Tranylcypromine—Haemorrhage—Methylprednisolone—multiple sclerosis	0.000478	0.00334	CcSEcCtD
Tranylcypromine—Hypertension—Mitoxantrone—multiple sclerosis	0.000477	0.00334	CcSEcCtD
Tranylcypromine—Diarrhoea—Cladribine—multiple sclerosis	0.00047	0.00328	CcSEcCtD
Tranylcypromine—Anxiety—Mitoxantrone—multiple sclerosis	0.000469	0.00328	CcSEcCtD
Tranylcypromine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000466	0.0111	CbGpPWpGaD
Tranylcypromine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000466	0.0111	CbGpPWpGaD
Tranylcypromine—Feeling abnormal—Azathioprine—multiple sclerosis	0.00046	0.00322	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000456	0.00319	CcSEcCtD
Tranylcypromine—Confusional state—Mitoxantrone—multiple sclerosis	0.000455	0.00318	CcSEcCtD
Tranylcypromine—Dizziness—Cladribine—multiple sclerosis	0.000454	0.00317	CcSEcCtD
Tranylcypromine—Oedema—Mitoxantrone—multiple sclerosis	0.000451	0.00316	CcSEcCtD
Tranylcypromine—Shock—Mitoxantrone—multiple sclerosis	0.000444	0.0031	CcSEcCtD
Tranylcypromine—Bradycardia—Betamethasone—multiple sclerosis	0.000443	0.00309	CcSEcCtD
Tranylcypromine—Bradycardia—Dexamethasone—multiple sclerosis	0.000443	0.00309	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000442	0.00309	CcSEcCtD
Tranylcypromine—Body temperature increased—Azathioprine—multiple sclerosis	0.000441	0.00309	CcSEcCtD
Tranylcypromine—Abdominal pain—Azathioprine—multiple sclerosis	0.000441	0.00309	CcSEcCtD
Tranylcypromine—Tachycardia—Mitoxantrone—multiple sclerosis	0.00044	0.00308	CcSEcCtD
Tranylcypromine—Haemoglobin—Dexamethasone—multiple sclerosis	0.000437	0.00306	CcSEcCtD
Tranylcypromine—Haemoglobin—Betamethasone—multiple sclerosis	0.000437	0.00306	CcSEcCtD
Tranylcypromine—Vomiting—Cladribine—multiple sclerosis	0.000436	0.00305	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000436	0.00305	CcSEcCtD
Tranylcypromine—Erectile dysfunction—Prednisone—multiple sclerosis	0.000436	0.00305	CcSEcCtD
Tranylcypromine—Haemorrhage—Dexamethasone—multiple sclerosis	0.000435	0.00304	CcSEcCtD
Tranylcypromine—Haemorrhage—Betamethasone—multiple sclerosis	0.000435	0.00304	CcSEcCtD
Tranylcypromine—Rash—Cladribine—multiple sclerosis	0.000433	0.00303	CcSEcCtD
Tranylcypromine—Dermatitis—Cladribine—multiple sclerosis	0.000432	0.00302	CcSEcCtD
Tranylcypromine—Anorexia—Mitoxantrone—multiple sclerosis	0.00043	0.00301	CcSEcCtD
Tranylcypromine—Ataxia—Methotrexate—multiple sclerosis	0.00043	0.00301	CcSEcCtD
Tranylcypromine—Headache—Cladribine—multiple sclerosis	0.00043	0.00301	CcSEcCtD
Tranylcypromine—Vision blurred—Prednisolone—multiple sclerosis	0.000427	0.00299	CcSEcCtD
Tranylcypromine—Hypotension—Mitoxantrone—multiple sclerosis	0.000422	0.00295	CcSEcCtD
Tranylcypromine—Nausea—Cladribine—multiple sclerosis	0.000408	0.00285	CcSEcCtD
Tranylcypromine—Syncope—Prednisolone—multiple sclerosis	0.000407	0.00284	CcSEcCtD
Tranylcypromine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000405	0.00283	CcSEcCtD
Tranylcypromine—Somnolence—Mitoxantrone—multiple sclerosis	0.000401	0.0028	CcSEcCtD
Tranylcypromine—CYP2E1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000399	0.0095	CbGpPWpGaD
Tranylcypromine—CYP2E1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000399	0.0095	CbGpPWpGaD
Tranylcypromine—Loss of consciousness—Prednisolone—multiple sclerosis	0.000399	0.00279	CcSEcCtD
Tranylcypromine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000392	0.00274	CcSEcCtD
Tranylcypromine—Hypertension—Prednisolone—multiple sclerosis	0.000392	0.00274	CcSEcCtD
Tranylcypromine—Constipation—Mitoxantrone—multiple sclerosis	0.000386	0.0027	CcSEcCtD
Tranylcypromine—Pain—Mitoxantrone—multiple sclerosis	0.000386	0.0027	CcSEcCtD
Tranylcypromine—Bradycardia—Prednisone—multiple sclerosis	0.000385	0.0027	CcSEcCtD
Tranylcypromine—Alopecia—Dexamethasone—multiple sclerosis	0.000384	0.00269	CcSEcCtD
Tranylcypromine—Alopecia—Betamethasone—multiple sclerosis	0.000384	0.00269	CcSEcCtD
Tranylcypromine—Diarrhoea—Azathioprine—multiple sclerosis	0.000382	0.00267	CcSEcCtD
Tranylcypromine—Haemoglobin—Prednisone—multiple sclerosis	0.000381	0.00266	CcSEcCtD
Tranylcypromine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00038	0.00904	CbGpPWpGaD
Tranylcypromine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00038	0.00904	CbGpPWpGaD
Tranylcypromine—Haemorrhage—Prednisone—multiple sclerosis	0.000379	0.00265	CcSEcCtD
Tranylcypromine—MAOA—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000376	0.00894	CbGpPWpGaD
Tranylcypromine—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000375	0.00892	CbGpPWpGaD
Tranylcypromine—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000375	0.00892	CbGpPWpGaD
Tranylcypromine—Syncope—Triamcinolone—multiple sclerosis	0.000374	0.00262	CcSEcCtD
Tranylcypromine—Syncope—Methylprednisolone—multiple sclerosis	0.000373	0.00261	CcSEcCtD
Tranylcypromine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000372	0.0026	CcSEcCtD
Tranylcypromine—Oedema—Prednisolone—multiple sclerosis	0.00037	0.00259	CcSEcCtD
Tranylcypromine—Dizziness—Azathioprine—multiple sclerosis	0.000369	0.00258	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000369	0.00258	CcSEcCtD
Tranylcypromine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000367	0.00256	CcSEcCtD
Tranylcypromine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000366	0.00256	CcSEcCtD
Tranylcypromine—MAOA—Neuronal System—KCNA3—multiple sclerosis	0.000364	0.00866	CbGpPWpGaD
Tranylcypromine—Shock—Prednisolone—multiple sclerosis	0.000364	0.00255	CcSEcCtD
Tranylcypromine—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000364	0.00255	CcSEcCtD
Tranylcypromine—Tachycardia—Prednisolone—multiple sclerosis	0.000361	0.00253	CcSEcCtD
Tranylcypromine—Hypertension—Triamcinolone—multiple sclerosis	0.00036	0.00252	CcSEcCtD
Tranylcypromine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00036	0.00856	CbGpPWpGaD
Tranylcypromine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00036	0.00856	CbGpPWpGaD
Tranylcypromine—Hypertension—Methylprednisolone—multiple sclerosis	0.000359	0.00251	CcSEcCtD
Tranylcypromine—Urticaria—Mitoxantrone—multiple sclerosis	0.000358	0.00251	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000358	0.0025	CcSEcCtD
Tranylcypromine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000357	0.00249	CcSEcCtD
Tranylcypromine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000357	0.00249	CcSEcCtD
Tranylcypromine—Vomiting—Azathioprine—multiple sclerosis	0.000355	0.00248	CcSEcCtD
Tranylcypromine—Anxiety—Methylprednisolone—multiple sclerosis	0.000353	0.00247	CcSEcCtD
Tranylcypromine—Drowsiness—Methotrexate—multiple sclerosis	0.000352	0.00246	CcSEcCtD
Tranylcypromine—Rash—Azathioprine—multiple sclerosis	0.000352	0.00246	CcSEcCtD
Tranylcypromine—Dermatitis—Azathioprine—multiple sclerosis	0.000352	0.00246	CcSEcCtD
Tranylcypromine—Flushing—Prednisone—multiple sclerosis	0.000351	0.00246	CcSEcCtD
Tranylcypromine—Headache—Azathioprine—multiple sclerosis	0.00035	0.00244	CcSEcCtD
Tranylcypromine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00035	0.00831	CbGpPWpGaD
Tranylcypromine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00035	0.00831	CbGpPWpGaD
Tranylcypromine—Dry mouth—Triamcinolone—multiple sclerosis	0.000347	0.00243	CcSEcCtD
Tranylcypromine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000347	0.00824	CbGpPWpGaD
Tranylcypromine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000347	0.00824	CbGpPWpGaD
Tranylcypromine—MAOA—Biological oxidations—CYP27B1—multiple sclerosis	0.000346	0.00822	CbGpPWpGaD
Tranylcypromine—MAOA—Biological oxidations—CYP24A1—multiple sclerosis	0.000346	0.00822	CbGpPWpGaD
Tranylcypromine—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000345	0.0082	CbGpPWpGaD
Tranylcypromine—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000345	0.0082	CbGpPWpGaD
Tranylcypromine—Confusional state—Methylprednisolone—multiple sclerosis	0.000342	0.00239	CcSEcCtD
Tranylcypromine—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000342	0.00813	CbGpPWpGaD
Tranylcypromine—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000342	0.00813	CbGpPWpGaD
Tranylcypromine—MAOB—nerve—multiple sclerosis	0.000341	0.12	CbGeAlD
Tranylcypromine—Oedema—Triamcinolone—multiple sclerosis	0.00034	0.00238	CcSEcCtD
Tranylcypromine—Syncope—Betamethasone—multiple sclerosis	0.000339	0.00237	CcSEcCtD
Tranylcypromine—Syncope—Dexamethasone—multiple sclerosis	0.000339	0.00237	CcSEcCtD
Tranylcypromine—Sweating—Methotrexate—multiple sclerosis	0.000338	0.00236	CcSEcCtD
Tranylcypromine—Shock—Triamcinolone—multiple sclerosis	0.000335	0.00234	CcSEcCtD
Tranylcypromine—Insomnia—Prednisolone—multiple sclerosis	0.000335	0.00234	CcSEcCtD
Tranylcypromine—Alopecia—Prednisone—multiple sclerosis	0.000335	0.00234	CcSEcCtD
Tranylcypromine—Shock—Methylprednisolone—multiple sclerosis	0.000334	0.00234	CcSEcCtD
Tranylcypromine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000333	0.00233	CcSEcCtD
Tranylcypromine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000333	0.00233	CcSEcCtD
Tranylcypromine—Paraesthesia—Prednisolone—multiple sclerosis	0.000332	0.00232	CcSEcCtD
Tranylcypromine—Tachycardia—Triamcinolone—multiple sclerosis	0.000332	0.00232	CcSEcCtD
Tranylcypromine—Nausea—Azathioprine—multiple sclerosis	0.000332	0.00232	CcSEcCtD
Tranylcypromine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000331	0.00232	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000329	0.0023	CcSEcCtD
Tranylcypromine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000329	0.0023	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000328	0.0023	CcSEcCtD
Tranylcypromine—Hypertension—Dexamethasone—multiple sclerosis	0.000327	0.00228	CcSEcCtD
Tranylcypromine—Hypertension—Betamethasone—multiple sclerosis	0.000327	0.00228	CcSEcCtD
Tranylcypromine—Asthenia—Mitoxantrone—multiple sclerosis	0.000324	0.00226	CcSEcCtD
Tranylcypromine—Anxiety—Betamethasone—multiple sclerosis	0.000321	0.00225	CcSEcCtD
Tranylcypromine—Anxiety—Dexamethasone—multiple sclerosis	0.000321	0.00225	CcSEcCtD
Tranylcypromine—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000319	0.00758	CbGpPWpGaD
Tranylcypromine—Haemoglobin—Methotrexate—multiple sclerosis	0.000318	0.00222	CcSEcCtD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—C4A—multiple sclerosis	0.000318	0.00756	CbGpPWpGaD
Tranylcypromine—Hypotension—Methylprednisolone—multiple sclerosis	0.000317	0.00222	CcSEcCtD
Tranylcypromine—Pain—Prednisolone—multiple sclerosis	0.000317	0.00221	CcSEcCtD
Tranylcypromine—Hepatitis—Methotrexate—multiple sclerosis	0.000316	0.00221	CcSEcCtD
Tranylcypromine—Haemorrhage—Methotrexate—multiple sclerosis	0.000316	0.00221	CcSEcCtD
Tranylcypromine—Vision blurred—Prednisone—multiple sclerosis	0.000311	0.00217	CcSEcCtD
Tranylcypromine—Oedema—Betamethasone—multiple sclerosis	0.000309	0.00216	CcSEcCtD
Tranylcypromine—Oedema—Dexamethasone—multiple sclerosis	0.000309	0.00216	CcSEcCtD
Tranylcypromine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000309	0.00216	CcSEcCtD
Tranylcypromine—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000308	0.00733	CbGpPWpGaD
Tranylcypromine—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000308	0.00733	CbGpPWpGaD
Tranylcypromine—Insomnia—Triamcinolone—multiple sclerosis	0.000308	0.00215	CcSEcCtD
Tranylcypromine—Insomnia—Methylprednisolone—multiple sclerosis	0.000307	0.00215	CcSEcCtD
Tranylcypromine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000306	0.00214	CcSEcCtD
Tranylcypromine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000305	0.00213	CcSEcCtD
Tranylcypromine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000305	0.00213	CcSEcCtD
Tranylcypromine—Anaemia—Prednisone—multiple sclerosis	0.000305	0.00213	CcSEcCtD
Tranylcypromine—Shock—Dexamethasone—multiple sclerosis	0.000304	0.00212	CcSEcCtD
Tranylcypromine—Shock—Betamethasone—multiple sclerosis	0.000304	0.00212	CcSEcCtD
Tranylcypromine—Agitation—Prednisone—multiple sclerosis	0.000303	0.00212	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000302	0.00211	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000302	0.00211	CcSEcCtD
Tranylcypromine—Tachycardia—Betamethasone—multiple sclerosis	0.000301	0.00211	CcSEcCtD
Tranylcypromine—Tachycardia—Dexamethasone—multiple sclerosis	0.000301	0.00211	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000299	0.00209	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000299	0.00209	CcSEcCtD
Tranylcypromine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000296	0.00704	CbGpPWpGaD
Tranylcypromine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000296	0.00704	CbGpPWpGaD
Tranylcypromine—Syncope—Prednisone—multiple sclerosis	0.000296	0.00207	CcSEcCtD
Tranylcypromine—Tinnitus—Methotrexate—multiple sclerosis	0.000295	0.00206	CcSEcCtD
Tranylcypromine—Anorexia—Dexamethasone—multiple sclerosis	0.000294	0.00206	CcSEcCtD
Tranylcypromine—Anorexia—Betamethasone—multiple sclerosis	0.000294	0.00206	CcSEcCtD
Tranylcypromine—Urticaria—Prednisolone—multiple sclerosis	0.000294	0.00206	CcSEcCtD
Tranylcypromine—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000292	0.00695	CbGpPWpGaD
Tranylcypromine—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000292	0.00695	CbGpPWpGaD
Tranylcypromine—Pain—Triamcinolone—multiple sclerosis	0.000291	0.00204	CcSEcCtD
Tranylcypromine—MAOA—nerve—multiple sclerosis	0.000291	0.102	CbGeAlD
Tranylcypromine—Loss of consciousness—Prednisone—multiple sclerosis	0.00029	0.00203	CcSEcCtD
Tranylcypromine—Hypotension—Dexamethasone—multiple sclerosis	0.000289	0.00202	CcSEcCtD
Tranylcypromine—Hypotension—Betamethasone—multiple sclerosis	0.000289	0.00202	CcSEcCtD
Tranylcypromine—Vomiting—Mitoxantrone—multiple sclerosis	0.000287	0.00201	CcSEcCtD
Tranylcypromine—Hypertension—Prednisone—multiple sclerosis	0.000285	0.00199	CcSEcCtD
Tranylcypromine—Rash—Mitoxantrone—multiple sclerosis	0.000284	0.00199	CcSEcCtD
Tranylcypromine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000284	0.00199	CcSEcCtD
Tranylcypromine—Chills—Methotrexate—multiple sclerosis	0.000284	0.00199	CcSEcCtD
Tranylcypromine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000283	0.00674	CbGpPWpGaD
Tranylcypromine—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000283	0.00674	CbGpPWpGaD
Tranylcypromine—Headache—Mitoxantrone—multiple sclerosis	0.000283	0.00198	CcSEcCtD
Tranylcypromine—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000281	0.00668	CbGpPWpGaD
Tranylcypromine—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000281	0.00668	CbGpPWpGaD
Tranylcypromine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000281	0.00196	CcSEcCtD
Tranylcypromine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00028	0.00196	CcSEcCtD
Tranylcypromine—Anxiety—Prednisone—multiple sclerosis	0.00028	0.00196	CcSEcCtD
Tranylcypromine—Alopecia—Methotrexate—multiple sclerosis	0.00028	0.00196	CcSEcCtD
Tranylcypromine—Insomnia—Betamethasone—multiple sclerosis	0.000279	0.00195	CcSEcCtD
Tranylcypromine—Insomnia—Dexamethasone—multiple sclerosis	0.000279	0.00195	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000278	0.00194	CcSEcCtD
Tranylcypromine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000277	0.00194	CcSEcCtD
Tranylcypromine—Paraesthesia—Betamethasone—multiple sclerosis	0.000277	0.00194	CcSEcCtD
Tranylcypromine—Urticaria—Triamcinolone—multiple sclerosis	0.00027	0.00189	CcSEcCtD
Tranylcypromine—Urticaria—Methylprednisolone—multiple sclerosis	0.00027	0.00189	CcSEcCtD
Tranylcypromine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000269	0.00188	CcSEcCtD
Tranylcypromine—Oedema—Prednisone—multiple sclerosis	0.000269	0.00188	CcSEcCtD
Tranylcypromine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000268	0.00188	CcSEcCtD
Tranylcypromine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000268	0.00188	CcSEcCtD
Tranylcypromine—Decreased appetite—Betamethasone—multiple sclerosis	0.000268	0.00188	CcSEcCtD
Tranylcypromine—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000268	0.00638	CbGpPWpGaD
Tranylcypromine—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000268	0.00638	CbGpPWpGaD
Tranylcypromine—Nausea—Mitoxantrone—multiple sclerosis	0.000268	0.00187	CcSEcCtD
Tranylcypromine—Shock—Prednisone—multiple sclerosis	0.000265	0.00185	CcSEcCtD
Tranylcypromine—Pain—Dexamethasone—multiple sclerosis	0.000264	0.00185	CcSEcCtD
Tranylcypromine—Pain—Betamethasone—multiple sclerosis	0.000264	0.00185	CcSEcCtD
Tranylcypromine—Tachycardia—Prednisone—multiple sclerosis	0.000263	0.00184	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Prednisone—multiple sclerosis	0.00026	0.00182	CcSEcCtD
Tranylcypromine—Vision blurred—Methotrexate—multiple sclerosis	0.00026	0.00182	CcSEcCtD
Tranylcypromine—Anorexia—Prednisone—multiple sclerosis	0.000256	0.00179	CcSEcCtD
Tranylcypromine—Anaemia—Methotrexate—multiple sclerosis	0.000255	0.00178	CcSEcCtD
Tranylcypromine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000255	0.00178	CcSEcCtD
Tranylcypromine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000255	0.00178	CcSEcCtD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000254	0.00604	CbGpPWpGaD
Tranylcypromine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000254	0.00604	CbGpPWpGaD
Tranylcypromine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000253	0.00177	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000253	0.00177	CcSEcCtD
Tranylcypromine—Leukopenia—Methotrexate—multiple sclerosis	0.000247	0.00172	CcSEcCtD
Tranylcypromine—Urticaria—Betamethasone—multiple sclerosis	0.000245	0.00172	CcSEcCtD
Tranylcypromine—Urticaria—Dexamethasone—multiple sclerosis	0.000245	0.00172	CcSEcCtD
Tranylcypromine—Dizziness—Prednisolone—multiple sclerosis	0.000245	0.00171	CcSEcCtD
Tranylcypromine—Asthenia—Triamcinolone—multiple sclerosis	0.000244	0.00171	CcSEcCtD
Tranylcypromine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000244	0.00171	CcSEcCtD
Tranylcypromine—Abdominal pain—Betamethasone—multiple sclerosis	0.000244	0.00171	CcSEcCtD
Tranylcypromine—Body temperature increased—Betamethasone—multiple sclerosis	0.000244	0.00171	CcSEcCtD
Tranylcypromine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000244	0.00171	CcSEcCtD
Tranylcypromine—Asthenia—Methylprednisolone—multiple sclerosis	0.000244	0.0017	CcSEcCtD
Tranylcypromine—Insomnia—Prednisone—multiple sclerosis	0.000243	0.0017	CcSEcCtD
Tranylcypromine—Paraesthesia—Prednisone—multiple sclerosis	0.000242	0.00169	CcSEcCtD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—AQP4—multiple sclerosis	0.000241	0.00573	CbGpPWpGaD
Tranylcypromine—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00024	0.00571	CbGpPWpGaD
Tranylcypromine—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00024	0.00571	CbGpPWpGaD
Tranylcypromine—Decreased appetite—Prednisone—multiple sclerosis	0.000234	0.00164	CcSEcCtD
Tranylcypromine—Rash—Prednisolone—multiple sclerosis	0.000233	0.00163	CcSEcCtD
Tranylcypromine—MAOB—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000233	0.00555	CbGpPWpGaD
Tranylcypromine—Dermatitis—Prednisolone—multiple sclerosis	0.000233	0.00163	CcSEcCtD
Tranylcypromine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000232	0.00163	CcSEcCtD
Tranylcypromine—Headache—Prednisolone—multiple sclerosis	0.000232	0.00162	CcSEcCtD
Tranylcypromine—Constipation—Prednisone—multiple sclerosis	0.00023	0.00161	CcSEcCtD
Tranylcypromine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000229	0.00543	CbGpPWpGaD
Tranylcypromine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000229	0.00543	CbGpPWpGaD
Tranylcypromine—Confusional state—Methotrexate—multiple sclerosis	0.000227	0.00159	CcSEcCtD
Tranylcypromine—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000226	0.00536	CbGpPWpGaD
Tranylcypromine—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000226	0.00536	CbGpPWpGaD
Tranylcypromine—Dizziness—Triamcinolone—multiple sclerosis	0.000225	0.00157	CcSEcCtD
Tranylcypromine—Dizziness—Methylprednisolone—multiple sclerosis	0.000225	0.00157	CcSEcCtD
Tranylcypromine—Feeling abnormal—Prednisone—multiple sclerosis	0.000222	0.00155	CcSEcCtD
Tranylcypromine—Asthenia—Betamethasone—multiple sclerosis	0.000222	0.00155	CcSEcCtD
Tranylcypromine—Asthenia—Dexamethasone—multiple sclerosis	0.000222	0.00155	CcSEcCtD
Tranylcypromine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.00022	0.00154	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00022	0.00154	CcSEcCtD
Tranylcypromine—Nausea—Prednisolone—multiple sclerosis	0.00022	0.00154	CcSEcCtD
Tranylcypromine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000217	0.00152	CcSEcCtD
Tranylcypromine—Vomiting—Triamcinolone—multiple sclerosis	0.000216	0.00151	CcSEcCtD
Tranylcypromine—Vomiting—Methylprednisolone—multiple sclerosis	0.000216	0.00151	CcSEcCtD
Tranylcypromine—Rash—Triamcinolone—multiple sclerosis	0.000215	0.0015	CcSEcCtD
Tranylcypromine—Dermatitis—Triamcinolone—multiple sclerosis	0.000214	0.0015	CcSEcCtD
Tranylcypromine—Anorexia—Methotrexate—multiple sclerosis	0.000214	0.0015	CcSEcCtD
Tranylcypromine—Rash—Methylprednisolone—multiple sclerosis	0.000214	0.0015	CcSEcCtD
Tranylcypromine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000214	0.0015	CcSEcCtD
Tranylcypromine—Urticaria—Prednisone—multiple sclerosis	0.000214	0.00149	CcSEcCtD
Tranylcypromine—Headache—Triamcinolone—multiple sclerosis	0.000213	0.00149	CcSEcCtD
Tranylcypromine—Headache—Methylprednisolone—multiple sclerosis	0.000213	0.00149	CcSEcCtD
Tranylcypromine—Body temperature increased—Prednisone—multiple sclerosis	0.000213	0.00149	CcSEcCtD
Tranylcypromine—Abdominal pain—Prednisone—multiple sclerosis	0.000213	0.00149	CcSEcCtD
Tranylcypromine—CYP2E1—Biological oxidations—CYP24A1—multiple sclerosis	0.000212	0.00504	CbGpPWpGaD
Tranylcypromine—CYP2E1—Biological oxidations—CYP27B1—multiple sclerosis	0.000212	0.00504	CbGpPWpGaD
Tranylcypromine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000211	0.00148	CcSEcCtD
Tranylcypromine—Diarrhoea—Betamethasone—multiple sclerosis	0.000211	0.00148	CcSEcCtD
Tranylcypromine—Hypotension—Methotrexate—multiple sclerosis	0.00021	0.00147	CcSEcCtD
Tranylcypromine—CYP2E1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000209	0.00497	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000209	0.00497	CbGpPWpGaD
Tranylcypromine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000205	0.00488	CbGpPWpGaD
Tranylcypromine—Dizziness—Betamethasone—multiple sclerosis	0.000204	0.00143	CcSEcCtD
Tranylcypromine—Dizziness—Dexamethasone—multiple sclerosis	0.000204	0.00143	CcSEcCtD
Tranylcypromine—Insomnia—Methotrexate—multiple sclerosis	0.000203	0.00142	CcSEcCtD
Tranylcypromine—Nausea—Triamcinolone—multiple sclerosis	0.000202	0.00141	CcSEcCtD
Tranylcypromine—Paraesthesia—Methotrexate—multiple sclerosis	0.000202	0.00141	CcSEcCtD
Tranylcypromine—Nausea—Methylprednisolone—multiple sclerosis	0.000202	0.00141	CcSEcCtD
Tranylcypromine—Somnolence—Methotrexate—multiple sclerosis	0.0002	0.0014	CcSEcCtD
Tranylcypromine—Vomiting—Betamethasone—multiple sclerosis	0.000196	0.00137	CcSEcCtD
Tranylcypromine—Vomiting—Dexamethasone—multiple sclerosis	0.000196	0.00137	CcSEcCtD
Tranylcypromine—Decreased appetite—Methotrexate—multiple sclerosis	0.000195	0.00137	CcSEcCtD
Tranylcypromine—Rash—Dexamethasone—multiple sclerosis	0.000195	0.00136	CcSEcCtD
Tranylcypromine—Rash—Betamethasone—multiple sclerosis	0.000195	0.00136	CcSEcCtD
Tranylcypromine—Dermatitis—Dexamethasone—multiple sclerosis	0.000195	0.00136	CcSEcCtD
Tranylcypromine—Dermatitis—Betamethasone—multiple sclerosis	0.000195	0.00136	CcSEcCtD
Tranylcypromine—Headache—Dexamethasone—multiple sclerosis	0.000193	0.00135	CcSEcCtD
Tranylcypromine—Headache—Betamethasone—multiple sclerosis	0.000193	0.00135	CcSEcCtD
Tranylcypromine—Asthenia—Prednisone—multiple sclerosis	0.000193	0.00135	CcSEcCtD
Tranylcypromine—Pain—Methotrexate—multiple sclerosis	0.000192	0.00134	CcSEcCtD
Tranylcypromine—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000185	0.00441	CbGpPWpGaD
Tranylcypromine—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000185	0.00441	CbGpPWpGaD
Tranylcypromine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000185	0.0013	CcSEcCtD
Tranylcypromine—Diarrhoea—Prednisone—multiple sclerosis	0.000184	0.00129	CcSEcCtD
Tranylcypromine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000184	0.00129	CcSEcCtD
Tranylcypromine—Nausea—Dexamethasone—multiple sclerosis	0.000183	0.00128	CcSEcCtD
Tranylcypromine—Nausea—Betamethasone—multiple sclerosis	0.000183	0.00128	CcSEcCtD
Tranylcypromine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000179	0.00425	CbGpPWpGaD
Tranylcypromine—Urticaria—Methotrexate—multiple sclerosis	0.000179	0.00125	CcSEcCtD
Tranylcypromine—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000178	0.00423	CbGpPWpGaD
Tranylcypromine—Dizziness—Prednisone—multiple sclerosis	0.000178	0.00124	CcSEcCtD
Tranylcypromine—Abdominal pain—Methotrexate—multiple sclerosis	0.000178	0.00124	CcSEcCtD
Tranylcypromine—Body temperature increased—Methotrexate—multiple sclerosis	0.000178	0.00124	CcSEcCtD
Tranylcypromine—Vomiting—Prednisone—multiple sclerosis	0.000171	0.0012	CcSEcCtD
Tranylcypromine—Rash—Prednisone—multiple sclerosis	0.00017	0.00119	CcSEcCtD
Tranylcypromine—Dermatitis—Prednisone—multiple sclerosis	0.000169	0.00118	CcSEcCtD
Tranylcypromine—Headache—Prednisone—multiple sclerosis	0.000169	0.00118	CcSEcCtD
Tranylcypromine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000164	0.00389	CbGpPWpGaD
Tranylcypromine—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	0.000164	0.00389	CbGpPWpGaD
Tranylcypromine—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	0.000164	0.00389	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000161	0.00384	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000161	0.00384	CbGpPWpGaD
Tranylcypromine—Asthenia—Methotrexate—multiple sclerosis	0.000161	0.00113	CcSEcCtD
Tranylcypromine—Nausea—Prednisone—multiple sclerosis	0.00016	0.00112	CcSEcCtD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000159	0.00379	CbGpPWpGaD
Tranylcypromine—Diarrhoea—Methotrexate—multiple sclerosis	0.000154	0.00108	CcSEcCtD
Tranylcypromine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000153	0.00363	CbGpPWpGaD
Tranylcypromine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000151	0.00358	CbGpPWpGaD
Tranylcypromine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000151	0.00358	CbGpPWpGaD
Tranylcypromine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000149	0.00355	CbGpPWpGaD
Tranylcypromine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000149	0.00355	CbGpPWpGaD
Tranylcypromine—Dizziness—Methotrexate—multiple sclerosis	0.000149	0.00104	CcSEcCtD
Tranylcypromine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000148	0.00353	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000148	0.00353	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000147	0.0035	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000147	0.0035	CbGpPWpGaD
Tranylcypromine—MAOA—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000146	0.00348	CbGpPWpGaD
Tranylcypromine—MAOB—brainstem—multiple sclerosis	0.000146	0.0513	CbGeAlD
Tranylcypromine—Vomiting—Methotrexate—multiple sclerosis	0.000143	0.000999	CcSEcCtD
Tranylcypromine—Rash—Methotrexate—multiple sclerosis	0.000142	0.000991	CcSEcCtD
Tranylcypromine—Dermatitis—Methotrexate—multiple sclerosis	0.000142	0.00099	CcSEcCtD
Tranylcypromine—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000141	0.00335	CbGpPWpGaD
Tranylcypromine—Headache—Methotrexate—multiple sclerosis	0.000141	0.000985	CcSEcCtD
Tranylcypromine—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.00014	0.00333	CbGpPWpGaD
Tranylcypromine—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000139	0.0033	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—SRM—multiple sclerosis	0.000134	0.00318	CbGpPWpGaD
Tranylcypromine—Nausea—Methotrexate—multiple sclerosis	0.000134	0.000934	CcSEcCtD
Tranylcypromine—MAOA—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000133	0.00317	CbGpPWpGaD
Tranylcypromine—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000128	0.00303	CbGpPWpGaD
Tranylcypromine—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000128	0.00303	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000126	0.00299	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000126	0.00299	CbGpPWpGaD
Tranylcypromine—MAOA—brainstem—multiple sclerosis	0.000125	0.0438	CbGeAlD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000125	0.00296	CbGpPWpGaD
Tranylcypromine—MAOB—Biological oxidations—POMC—multiple sclerosis	0.000124	0.00295	CbGpPWpGaD
Tranylcypromine—MAOA—retina—multiple sclerosis	0.00012	0.0422	CbGeAlD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000119	0.00283	CbGpPWpGaD
Tranylcypromine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000118	0.0028	CbGpPWpGaD
Tranylcypromine—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000114	0.0027	CbGpPWpGaD
Tranylcypromine—CYP2E1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000111	0.00263	CbGpPWpGaD
Tranylcypromine—MAOA—Neuronal System—BCHE—multiple sclerosis	0.000102	0.00243	CbGpPWpGaD
Tranylcypromine—MAOB—medulla oblongata—multiple sclerosis	0.000102	0.0358	CbGeAlD
Tranylcypromine—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	9.84e-05	0.00234	CbGpPWpGaD
Tranylcypromine—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	9.84e-05	0.00234	CbGpPWpGaD
Tranylcypromine—CYP2A6—cerebellum—multiple sclerosis	9.77e-05	0.0343	CbGeAlD
Tranylcypromine—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	9.71e-05	0.00231	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	9.71e-05	0.00231	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—CYP24A1—multiple sclerosis	9.42e-05	0.00224	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—CYP27B1—multiple sclerosis	9.42e-05	0.00224	CbGpPWpGaD
Tranylcypromine—MAOB—midbrain—multiple sclerosis	9.32e-05	0.0327	CbGeAlD
Tranylcypromine—MAOB—spinal cord—multiple sclerosis	9.09e-05	0.0319	CbGeAlD
Tranylcypromine—CYP2E1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.98e-05	0.00214	CbGpPWpGaD
Tranylcypromine—MAOA—medulla oblongata—multiple sclerosis	8.7e-05	0.0305	CbGeAlD
Tranylcypromine—MAOB—Metabolism—GPC5—multiple sclerosis	8.62e-05	0.00205	CbGpPWpGaD
Tranylcypromine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.55e-05	0.00203	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—SRM—multiple sclerosis	8.39e-05	0.002	CbGpPWpGaD
Tranylcypromine—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—multiple sclerosis	8.18e-05	0.00195	CbGpPWpGaD
Tranylcypromine—MAOA—midbrain—multiple sclerosis	7.95e-05	0.0279	CbGeAlD
Tranylcypromine—CYP2A6—brain—multiple sclerosis	7.93e-05	0.0279	CbGeAlD
Tranylcypromine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.86e-05	0.00187	CbGpPWpGaD
Tranylcypromine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.8e-05	0.00185	CbGpPWpGaD
Tranylcypromine—MAOA—Biological oxidations—POMC—multiple sclerosis	7.78e-05	0.00185	CbGpPWpGaD
Tranylcypromine—MAOA—spinal cord—multiple sclerosis	7.76e-05	0.0272	CbGeAlD
Tranylcypromine—MAOB—nervous system—multiple sclerosis	7.66e-05	0.0269	CbGeAlD
Tranylcypromine—CYP2D6—brainstem—multiple sclerosis	7.41e-05	0.026	CbGeAlD
Tranylcypromine—MAOB—central nervous system—multiple sclerosis	7.37e-05	0.0259	CbGeAlD
Tranylcypromine—MAOB—cerebellum—multiple sclerosis	7.21e-05	0.0253	CbGeAlD
Tranylcypromine—MAOB—Metabolism—RRM1—multiple sclerosis	7.14e-05	0.0017	CbGpPWpGaD
Tranylcypromine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.93e-05	0.00165	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	6.85e-05	0.00163	CbGpPWpGaD
Tranylcypromine—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.66e-05	0.00158	CbGpPWpGaD
Tranylcypromine—MAOA—nervous system—multiple sclerosis	6.53e-05	0.0229	CbGeAlD
Tranylcypromine—CYP2E1—medulla oblongata—multiple sclerosis	6.53e-05	0.0229	CbGeAlD
Tranylcypromine—CYP2A6—Metabolism—SRM—multiple sclerosis	6.52e-05	0.00155	CbGpPWpGaD
Tranylcypromine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.37e-05	0.00152	CbGpPWpGaD
Tranylcypromine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.32e-05	0.0015	CbGpPWpGaD
Tranylcypromine—MAOA—central nervous system—multiple sclerosis	6.29e-05	0.0221	CbGeAlD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	6.28e-05	0.00149	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	6.28e-05	0.00149	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	6.24e-05	0.00148	CbGpPWpGaD
Tranylcypromine—MAOA—cerebellum—multiple sclerosis	6.15e-05	0.0216	CbGeAlD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	6.11e-05	0.00145	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	6.09e-05	0.00145	CbGpPWpGaD
Tranylcypromine—CYP2A6—Biological oxidations—POMC—multiple sclerosis	6.04e-05	0.00144	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—CYP24A1—multiple sclerosis	5.91e-05	0.00141	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—CYP27B1—multiple sclerosis	5.91e-05	0.00141	CbGpPWpGaD
Tranylcypromine—MAOB—brain—multiple sclerosis	5.85e-05	0.0206	CbGeAlD
Tranylcypromine—CYP2E1—spinal cord—multiple sclerosis	5.82e-05	0.0204	CbGeAlD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.73e-05	0.00136	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.73e-05	0.00136	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—GPC5—multiple sclerosis	5.41e-05	0.00129	CbGpPWpGaD
Tranylcypromine—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.4e-05	0.00128	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—SRM—multiple sclerosis	5.15e-05	0.00122	CbGpPWpGaD
Tranylcypromine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.14e-05	0.00122	CbGpPWpGaD
Tranylcypromine—MAOA—brain—multiple sclerosis	4.99e-05	0.0175	CbGeAlD
Tranylcypromine—CYP2E1—nervous system—multiple sclerosis	4.9e-05	0.0172	CbGeAlD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.9e-05	0.00116	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.9e-05	0.00116	CbGpPWpGaD
Tranylcypromine—CYP2E1—Biological oxidations—POMC—multiple sclerosis	4.77e-05	0.00113	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	4.76e-05	0.00113	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	4.75e-05	0.00113	CbGpPWpGaD
Tranylcypromine—CYP2E1—central nervous system—multiple sclerosis	4.72e-05	0.0166	CbGeAlD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	4.66e-05	0.00111	CbGpPWpGaD
Tranylcypromine—CYP2E1—cerebellum—multiple sclerosis	4.62e-05	0.0162	CbGeAlD
Tranylcypromine—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	4.59e-05	0.00109	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	4.59e-05	0.00109	CbGpPWpGaD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.53e-05	0.00108	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—RRM1—multiple sclerosis	4.48e-05	0.00107	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	4.44e-05	0.00105	CbGpPWpGaD
Tranylcypromine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	4.44e-05	0.00105	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—GPC5—multiple sclerosis	4.2e-05	0.000998	CbGpPWpGaD
Tranylcypromine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.17e-05	0.000991	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—BCHE—multiple sclerosis	4.1e-05	0.000975	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—SRM—multiple sclerosis	3.97e-05	0.000945	CbGpPWpGaD
Tranylcypromine—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	3.97e-05	0.000944	CbGpPWpGaD
Tranylcypromine—CYP3A4—nervous system—multiple sclerosis	3.95e-05	0.0139	CbGeAlD
Tranylcypromine—MAOA—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.9e-05	0.000927	CbGpPWpGaD
Tranylcypromine—CYP2D6—nervous system—multiple sclerosis	3.88e-05	0.0136	CbGeAlD
Tranylcypromine—CYP3A4—central nervous system—multiple sclerosis	3.8e-05	0.0133	CbGeAlD
Tranylcypromine—CYP2E1—brain—multiple sclerosis	3.75e-05	0.0132	CbGeAlD
Tranylcypromine—CYP2D6—central nervous system—multiple sclerosis	3.74e-05	0.0131	CbGeAlD
Tranylcypromine—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.68e-05	0.000875	CbGpPWpGaD
Tranylcypromine—CYP2D6—cerebellum—multiple sclerosis	3.65e-05	0.0128	CbGeAlD
Tranylcypromine—MAOA—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.65e-05	0.000869	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—SRM—multiple sclerosis	3.65e-05	0.000869	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—CYP27B1—multiple sclerosis	3.63e-05	0.000863	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—CYP24A1—multiple sclerosis	3.63e-05	0.000863	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—SRM—multiple sclerosis	3.62e-05	0.000861	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—RRM1—multiple sclerosis	3.48e-05	0.000827	CbGpPWpGaD
Tranylcypromine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	3.39e-05	0.000805	CbGpPWpGaD
Tranylcypromine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	3.36e-05	0.000798	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—GPC5—multiple sclerosis	3.32e-05	0.000789	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—SRM—multiple sclerosis	3.1e-05	0.000736	CbGpPWpGaD
Tranylcypromine—MAOA—Neuronal System—MAPK1—multiple sclerosis	2.99e-05	0.00071	CbGpPWpGaD
Tranylcypromine—CYP2D6—brain—multiple sclerosis	2.97e-05	0.0104	CbGeAlD
Tranylcypromine—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.87e-05	0.000682	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.8e-05	0.000665	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.8e-05	0.000665	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—RRM1—multiple sclerosis	2.75e-05	0.000654	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.74e-05	0.00065	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.57e-05	0.000612	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.57e-05	0.000612	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—BCHE—multiple sclerosis	2.57e-05	0.000612	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.56e-05	0.000609	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2.55e-05	0.000607	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2.55e-05	0.000607	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.49e-05	0.000593	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—APOE—multiple sclerosis	2.47e-05	0.000587	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—SRM—multiple sclerosis	2.39e-05	0.000568	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.35e-05	0.00056	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—GPC5—multiple sclerosis	2.33e-05	0.000555	CbGpPWpGaD
Tranylcypromine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.21e-05	0.000526	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	2.18e-05	0.000519	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	2.18e-05	0.000519	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.13e-05	0.000507	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—RRM1—multiple sclerosis	2.12e-05	0.000504	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—POMC—multiple sclerosis	2.12e-05	0.000504	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—BCHE—multiple sclerosis	2e-05	0.000475	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.99e-05	0.000474	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.95e-05	0.000464	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.93e-05	0.00046	CbGpPWpGaD
Tranylcypromine—MAOB—Metabolism—ALB—multiple sclerosis	1.93e-05	0.00046	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.68e-05	0.0004	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.68e-05	0.0004	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.65e-05	0.000393	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.65e-05	0.000391	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—BCHE—multiple sclerosis	1.58e-05	0.000375	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—APOE—multiple sclerosis	1.55e-05	0.000368	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.54e-05	0.000366	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.5e-05	0.000357	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.41e-05	0.000336	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—POMC—multiple sclerosis	1.33e-05	0.000316	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.29e-05	0.000307	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.29e-05	0.000306	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.28e-05	0.000305	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.28e-05	0.000303	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.22e-05	0.00029	CbGpPWpGaD
Tranylcypromine—MAOA—Metabolism—ALB—multiple sclerosis	1.21e-05	0.000288	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—APOE—multiple sclerosis	1.2e-05	0.000286	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.18e-05	0.000279	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.12e-05	0.000266	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.11e-05	0.000264	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.1e-05	0.000262	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—POMC—multiple sclerosis	1.03e-05	0.000246	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1e-05	0.000239	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—APOE—multiple sclerosis	9.5e-06	0.000226	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—BCHE—multiple sclerosis	9.49e-06	0.000226	CbGpPWpGaD
Tranylcypromine—CYP2A6—Metabolism—ALB—multiple sclerosis	9.41e-06	0.000224	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—POMC—multiple sclerosis	8.16e-06	0.000194	CbGpPWpGaD
Tranylcypromine—CYP2E1—Metabolism—ALB—multiple sclerosis	7.44e-06	0.000177	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—APOE—multiple sclerosis	7.33e-06	0.000174	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—BCHE—multiple sclerosis	7.33e-06	0.000174	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—APOE—multiple sclerosis	6.74e-06	0.00016	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—APOE—multiple sclerosis	6.68e-06	0.000159	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—POMC—multiple sclerosis	6.3e-06	0.00015	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—POMC—multiple sclerosis	5.79e-06	0.000138	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—POMC—multiple sclerosis	5.74e-06	0.000136	CbGpPWpGaD
Tranylcypromine—CYP2C19—Metabolism—ALB—multiple sclerosis	5.74e-06	0.000136	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—APOE—multiple sclerosis	5.71e-06	0.000136	CbGpPWpGaD
Tranylcypromine—CYP2D6—Metabolism—ALB—multiple sclerosis	5.28e-06	0.000126	CbGpPWpGaD
Tranylcypromine—CYP2C9—Metabolism—ALB—multiple sclerosis	5.23e-06	0.000124	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—POMC—multiple sclerosis	4.91e-06	0.000117	CbGpPWpGaD
Tranylcypromine—CYP1A2—Metabolism—ALB—multiple sclerosis	4.47e-06	0.000106	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—APOE—multiple sclerosis	4.41e-06	0.000105	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—POMC—multiple sclerosis	3.79e-06	9e-05	CbGpPWpGaD
Tranylcypromine—CYP3A4—Metabolism—ALB—multiple sclerosis	3.45e-06	8.21e-05	CbGpPWpGaD
